Úneta a la lista de correo. Requiere aprobación
Correo electrónico:
Consultar este grupo

jueves, 29 de enero de 2015

Feasibility of establishing a BSL3 tuberculosis culture lab in a resource-limited setting

Background: Despite the recent innovations in tuberculosis (TB) and multi-drug resistant TB (MDR-TB) diagnosis, culture remains vital for difficult-to-diagnose patients, baseline and end-point determination for novel vaccines and drug trials. Herein, we share our experience of establishing a BSL-3 culture facility in Uganda as well as 3-years performance indicators and post-TB vaccine trials (pioneer) and funding experience of sustaining such a facility.
Methods: Between September 2008 and April 2009, the laboratory was set-up with financial support from external partners. After an initial procedure validation phase in parallel with the National TB Reference Laboratory (NTRL) and legal approvals, the laboratory registered for external quality assessment (EQA) from the NTRL, WHO, National Health Laboratories Services (NHLS), and the College of American Pathologists (CAP). The laboratory also instituted a functional quality management system (QMS). Pioneer funding ended in 2012 and the laboratory remained in self-sustainability mode.
Results: The laboratory achieved internationally acceptable standards in both structural and biosafety requirements. Of the 14 patient samples analyzed in the procedural validation phase, agreement for all tests with NTRL was 90% (P <0.01). It started full operations in October 2009 performing smear microscopy, culture, identification, and drug susceptibility testing (DST). The annual culture workload was 7,636, 10,242, and 2,712 inoculations for the years 2010, 2011, and 2012, respectively. Other performance indicators of TB culture laboratories were also monitored. Scores from EQA panels included smear microscopy >80% in all years from NTRL, CAP, and NHLS, and culture was 100% for CAP panels and above regional average scores for all years with NHLS. Quarterly DST scores from WHO-EQA ranged from 78% to 100% in 2010, 80% to 100% in 2011, and 90 to 100% in 2012.
Conclusions: From our experience, it is feasible to set-up a BSL-3 TB culture laboratory with acceptable quality performance standards in resource-limited countries. With the demonstrated quality of work, the laboratory attracted more research groups and post-pioneer funding, which helped to ensure sustainability. The high skilled experts in this research laboratory also continue to provide an excellent resource for the needed national discussion of the laboratory and quality management systems.
Ssengooba, W., et al. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda. Health Research Policy and Systems 2015, 13:4

Sigue este Blog en Facebook y Twitter

lunes, 26 de enero de 2015

License to Serve - U.S. Trainees and the #Ebola Epidemic

Before medical school, Sara L., now a fourth-year resident, worked for 6 years as a microbiologist at the Centers for Disease Control and Prevention. While there, she focused on hemorrhagic fevers, and she went to West Africa several times to assist in outbreaks. Indeed, until recently, Sara was one of only a few hundred people in the United States who was trained to work in a biosafety level 4 “spacesuit” laboratory, which requires the same personal protective equipment (PPE) needed for working with Ebola. As the current Ebola epidemic exploded, and after careful deliberation, Sara sought and secured a position with an international aid organization, got approval from her residency program's leadership, found coverage for her time away, and 6 weeks later, was set to deploy. Then she got a call from her institution's risk-management department with disappointing news: the institution would not support her deployment.

Rosenbaum L. License to Serve — U.S. Trainees and the Ebola Epidemic. N Engl J Med. 2014 Dec 17. 
Sigue este Blog en Facebook y Twitter

viernes, 23 de enero de 2015

The hidden face of academic researches on classified highly pathogenic microorganisms

Highly pathogenic microorganisms and toxins are manipulated in academic laboratories for fundamental research purposes, diagnostics, drugs and vaccines development. Obviously, these infectious pathogens represent a potential risk for human and/or animal health and their accidental or intentional release (biosafety and biosecurity, respectively) is a major concern of governments. In the past decade, several incidents have occurred in laboratories and reported by media causing fear and raising a sense of suspicion against biologists. Some scientists have been ordered by US government to leave their laboratory for long periods of time following the occurrence of an incident involving infectious pathogens; in other cases laboratories have been shut down and universities have been forced to pay fines and incur a long-term ban on funding after gross negligence of biosafety/biosecurity procedures. Measures of criminal sanctions have also been taken to minimize the risk that such incidents can reoccur.
Devaux CA. The hidden face of academic researches on classified highly pathogenic microorganisms. Infect Genet Evol. 2015 Jan;29:26-34. doi: 10.1016/j.meegid.2014.10.028. Epub 2014 Nov 7.
Sigue este Blog en Facebook y Twitter

jueves, 15 de enero de 2015

Preventing Worker Fatigue Among #Ebola Healthcare Workers #CDC

The National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA) recognize that healthcare workers and responders involved with cases related to Ebola in the United States may be required to work longer or unusual shifts. This can involve extended shifts (more than 8 hours long), rotating or irregular shifts, or consecutive shifts resulting in more than the typical 40-hour work week. Long work hours may increase the risk of injuries and accidents and can contribute to poor health and worker fatigue.
Additionally, the personal protective equipment (PPE) required for working with Ebola patients can increase workers’ core body temperature, contributing significantly to fatigue. Although these guidelines are geared toward workers responding in the United States, the same concepts apply to those working in other countries.

Sigue este Blog en Facebook y Twitter

martes, 13 de enero de 2015

A los patrocinadores de #AMexBio

Las personas interesadas en promover sus productos en el próximo VII Simposio de Bioseguridad y Biocustodia de la Asociación Mexicana de Bioseguridad A.C. Existen amplias oportunidades para posicionar sus marcas ante este público especializado.​
Mayor información con:

Cristina Wilhelm 

Guillermo Wilhelm Ferriz
Nextel Id: 52*167789*3
Tel Fijo: (473) 732-4681
Tel Celular: (55) 4410-6383
Sigue este Blog en Facebook y Twitter

miércoles, 10 de diciembre de 2014

Membresías AMEXBIO 2015

Para apoyar el cumplimiento de los objetivos de la Asociación Mexicana de Bioseguirdad A.C. se está llevando a cabo la campaña de renovación y actualización de membresía 2014 - 2015, la cual nos permitirá desarrollar distintos proyectos como asambleas, simposio, cursos en línea, seminarios, talleres, y otorgar un mayor número de becas para los asistentes. Una de las fuentes de ingreso de AMEXBIO son las aportaciones de los miembros, por lo que invitamos a actualizar su membresía o unirse como miembro activo.

Los BENEFICIOS que obtendrás al pagar tu membresía de 2015 son:
  1. Cuotas preferenciales para el Simposio Anual, cursos en línea, eventos, seminarios y productos que organice y promueva AMEXBIO.
  2. Accesos a la biblioteca de videos y cursos en nuestro portal de Formación Académica, a través de clave personalizada que te llegará al pagar tu membresía.
  3. Poder conocer las diferentes convocatorias de las instituciones que apoyan con recursos o descuentos para participar en eventos nacionales e internacionales sobre temas de bioseguridad.
  4. Contar con su perfil académico y poder participar como profesor en nuestros cursos en línea o cursos presenciales.
  5. Participar activamente en todos los eventos académicos que organice nuestra Asociación.
  6. Constancia de miembro activo.
Para lograr este objetivo, aprovecha el “Plan 2015 AMEXBIO” que consiste en:

A partir de 01-Febrero-2015, el costo de la Membresía se incrementa a $900.- MXN.
  1. Nuevos miembros. Si no eres miembro (Estatus visitante o en blanco): Los profesores o investigadores de nuevo ingreso deberán enviar el pago de $ 800.00 (Antes del 31 de Enero),  actualizar su perfil en la página de miembros: www.amexbio.wildapricot.org y enviar la documentación solicitada, al correo electrónico de tesoreria(arroba)amexbio.org. Por favor revisen la convocatoria en: http://amexbio.org/docs/convocatoriaM.pdf. A partir del 1 de Febrero, el costo será de $900.- (MXN). 
  2. Renovaciones miembros activos.  Si ya eres miembro y estas al corriente (Estatus Active): Paga el mismo importe del 2014 de $ 800.00 (actualiza tu perfil, hay campos nuevos). A partir del 01 de Febrero de 2015, incrementa a $ 900.- MXN
  3. Renovaciones vencidas, pagos pendientes. Si ya eres miembro pero no estás al corriente (Estatus Pending Renewal o Lapsed): Los miembros fundadores, titulares y numerarios que hayan dejado de pagar por varios años, podrán ponerse al corriente con todas sus cuotas al pagar $ 400.00, además de pagar lo correspondiente a la membresía 2015 de $ 800.00. En total del depósito sería de $ 1,200.00 para ponerse al corriente y renovar hasta febrero de 2016. (actualiza tu perfil, hay campos nuevos).
Las solicitudes nuevas se reciben de ENERO a MAYO de cada año!

Depósito bancario a nombre de:Cliente: ASOCIACION MEXICANA DE BIOSEGURIDAD A.C.
CLABE interbancaria: 002180024179950244
Sucursal: 0241
Cuenta: 7995024
Referencia: (nombre del miembro)
Enviar el comprobante de depósito escaneado y datos de facturación (si es necesario) y en el caso de nuevo ingreso, los documentos solicitados, al siguiente correo electrónico: tesoreria(arroba)amexbio.org. Se emitirá la factura correspondiente, la emisión de la clave de acceso para el portal de Formación Académica, así como la constancia de membresía, que se enviarán por correo electrónico.

Por favor ayúdanos a distribuir esta información entre tus contactos que les pueda interesar en participar en AMEXBIO.


Dr. Saúl López Silva
Consejo Directivo AMEXBIO

Sigue este Blog en Facebook y Twitter

lunes, 8 de diciembre de 2014

Plant-made #vaccine antigens against #malaria

This paper is an overview of vaccine antigens against malaria produced in plants. Plant-based expression systems represent an interesting production platform due to their reduced manufacturing costs and high scalability. At present, different Plasmodium antigens and expression strategies have been optimized in plants. Furthermore, malaria antigens are one of the few examples of eukaryotic proteins with vaccine value expressed in plants, making plant-derived malaria antigens an interesting model to analyze. Up to now, malaria antigen expression in plants has allowed the complete synthesis of these vaccine antigens, which have been able to induce an active immune response in mice. Therefore, plant production platforms offer wonderful prospects for improving the access to malaria vaccines.

Clemente M, Corigliano MG. Overview of plant-made vaccine antigens against malaria. J Biomed Biotechnol. 2012;2012:206918.
Sigue este Blog en Facebook y Twitter

jueves, 4 de diciembre de 2014

Conferencia: "#Ebola, panorama epidemiológico"

Impartida por el Dr. Mario Martínez González.
Asesor de la Organización Panamericana de Salud.

Lunes 8 de diciembre del 2014
De 12:00 a 14:00 hrs.
En la sala 2 del Auditorio de la Unidad de Posgrado,
Universidad Nacional Autónoma de México
Sigue este Blog en Facebook y Twitter

martes, 2 de diciembre de 2014

Alberto Díaz Quiñonez, recibe el "IFBA Biosafety Heroes Award 2014" #AMexBio

El Dr. José Alberto Díaz Quiñonez, Miembro Fundador y Presidente del Consejo Directivo 2011-2012 de la Asociación Mexicana de Bioseguridad obtuvo el reconocimiento "IFBA Biosafety Heroes Award 2014" otorgado por la International Federation of Biosafety Associations.
Este galardón fue creado por la IFBA en 2011, con el objetivo de reconocer a los profesionales que realizan contribuciones importantes en temas de gestión del riesgo biológico en el mundo. 
De acuerdo con IFBA el "Dr. Díaz Quiñonez ha demostrado ser un incansable promotor de la cultura de gestión del riesgo biológico en México".
Felicidades Alberto!
Sigue este Blog en Facebook y Twitter

viernes, 28 de noviembre de 2014

Chimpanzee Adenovirus Vector #Ebola Vaccine - Preliminary Report.

The unprecedented 2014 epidemic of Ebola virus disease (EVD) has prompted an international response to accelerate the availability of a preventive vaccine. A replication-defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species that offers protection in the nonhuman primate model, was rapidly advanced into phase 1 clinical evaluation. 
We conducted a phase 1, dose-escalation, open-label trial of cAd3-EBO. Twenty healthy adults, in sequentially enrolled groups of 10 each, received vaccination intramuscularly in doses of 2×1010 particle units or 2×1011 particle units. Primary and secondary end points related to safety and immunogenicity were assessed throughout the first 4 weeks after vaccination. 
In this small study, no safety concerns were identified; however, transient fever developed within 1 day after vaccination in two participants who had received the 2×1011 particle-unit dose. Glycoprotein-specific antibodies were induced in all 20 participants; the titers were of greater magnitude in the group that received the 2×1011 particle-unit dose than in the group that received the 2×1010 particle-unit dose (geometric mean titer against the Zaire antigen, 2037 vs. 331; P=0.001). Glycoprotein-specific T-cell responses were more frequent among those who received the 2x1011 particle-unit dose than among those who received the 2×1010 particle-unit dose, with a CD4 response in 10 of 10 participants versus 3 of 10 participants (P=0.004) and a CD8 response in 7 of 10 participants versus 2 of 10 participants (P=0.07). 
Reactogenicity and immune responses to cAd3-EBO vaccine were dose-dependent. At the 2×1011 particle-unit dose, glycoprotein Zaire-specific antibody responses were in the range reported to be associated with vaccine-induced protective immunity in challenge studies involving nonhuman primates. Clinical trials assessing cAd3-EBO are ongoing. (Funded by the Intramural Research Program of the National Institutes of Health; VRC 207 ClinicalTrials.gov number, NCT02231866 .).

Ledgerwood JE, et al; the VRC 207 Study Team. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. N Engl J Med. 2014 Nov 26. [Epub ahead of print] PubMed PMID: 25426834.


Related Posts Plugin for WordPress, Blogger...